Research reviewed by Gram suggests that photobiomodulation, a low-level light therapy, may prevent severe mouth sores in patients receiving stem cell transplants. In the POMFITT trial of 30 patients, none of 15 treated patients developed severe sores, compared with 4 of 15 control patients. Larger studies are still needed.

A Gram Research analysis of a 2026 review in Photodiagnosis and Photodynamic Therapy looked at whether photobiomodulation, a treatment that uses low-level light to support tissue healing, can protect the mouth during stem cell transplants. Mouth sores, called oral mucositis, are a common and painful side effect of the high-dose treatment patients receive before a transplant. In one small trial called POMFITT, involving 30 patients, none of the 15 people who received the light therapy developed severe mouth sores, compared with 4 of 15 people in the control group. The research suggests the therapy may be most useful for preventing mouth sores in this specific setting. However, the trial was very small, and the size of the difference depended on the statistical method used. Light therapy did not show clear differences in hospital stays, physical strength, or quality of life at discharge. Researchers say larger studies are needed before the therapy can be considered a full supportive treatment for patients.

Key Statistics

A 2026 review published in Photodiagnosis and Photodynamic Therapy found that in the 30-patient POMFITT trial, 0 of 15 stem cell transplant patients receiving light therapy developed severe mouth sores, compared with 4 of 15 control patients.

The same 2026 review reported that hospitalization, physical function, and quality of life did not differ significantly between light therapy and control groups at hospital discharge in the POMFITT trial.

The Quick Take

  • What they studied: Whether a low-level light treatment called photobiomodulation can prevent painful mouth sores in people getting stem cell transplants, and whether it also provides other benefits beyond protecting the mouth.
  • Who participated: The main evidence came from a small trial called POMFITT with 30 adults receiving stem cell transplants, split into two groups of 15. The review also looked at guidelines, other transplant studies, and some children’s studies, though those were less direct.
  • Key finding: In the POMFITT trial, none of the 15 patients who received light therapy developed severe mouth sores, compared with 4 of 15 patients who did not, a difference of about 27 percentage points. Because the groups were so small, this result may change depending on how the numbers are analyzed. Hospital stays, physical function, and quality of life did not differ clearly between the groups.
  • What it means for you: If you or a loved one is preparing for a stem cell transplant, light therapy may be an option to ask about for preventing mouth sores. It should be discussed with your transplant team, since the evidence is promising but still limited and it is not yet proven to improve overall recovery.

The Research Details

This publication is a critical narrative review, which means the authors read and summarized existing research rather than running a new experiment of their own. They focused on clinical trials in stem cell transplant patients, treatment guidelines, and more recent studies on the topic. The authors also made a point of separating studies they could fully review from those they could only see as short conference summaries, so readers can judge how strong each piece of evidence is.

The central study they examined, POMFITT, was a small comparison trial in which some patients received light therapy to the mouth while others received standard care. Comparing the two groups allowed researchers to see whether the treatment made a difference in mouth sores and other outcomes. Because the trial was small, even a few patients changing outcomes can shift the results noticeably.

The review also included children’s studies and abstract-only reports, which were used with caution. These sources helped the authors identify what is known and what still needs to be tested in larger, more carefully designed research.

A narrative review like this one is useful because it pulls together scattered evidence and explains where the strongest and weakest parts of the research lie. For a treatment that is still being studied, that kind of honest map helps doctors and patients understand what has been shown and what has not. It also prevents a single small trial from being mistaken for proof of broad benefits.

The review is transparent about its own limits, clearly labeling which sources were full studies and which were preliminary summaries. Its main evidence comes from one small trial, which makes the results less certain. The authors also note that the statistical method chosen can change how strong the result looks, so the findings should be read as encouraging rather than conclusive. Readers should also know that the review does not include a detailed record of every database search, so it is not a full systematic review.

What the Results Show

The clearest result comes from the POMFITT trial, where severe mouth sores occurred in 0 of 15 patients who received light therapy and in 4 of 15 patients in the control group. That gap of about 27 percentage points suggests the therapy may help prevent the most serious form of mouth sores in people receiving stem cell transplants. Mouth sores are a major problem in this setting because they can make eating, drinking, and swallowing very difficult during an already demanding recovery.

However, the numbers are very small. With only 30 patients, a change of just one or two people in either group could make the difference look larger or smaller. The authors point out that this type of sparse comparison is sensitive to the statistical test used, so the exact strength of the result should be interpreted carefully.

The review also looked at broader outcomes beyond the mouth. Hospitalization, physical function, and quality of life did not differ significantly between the groups at discharge. This means the trial did not show clear wider benefits, although it was not designed to detect every possible effect.

The review noted that mouth sores are linked with other problems during transplant recovery, including infections, the need for stronger pain medicine such as opioids, and difficulty getting enough nutrition. These links are important, but they are associations, which means they show that the problems often occur together without proving that light therapy would fix them. Children’s studies and abstract-only reports suggested possible benefits for some supportive-care outcomes, but these findings are preliminary and indirect.

The review places light therapy in line with earlier transplant and cancer-care research that treats mouth sores as a key target for prevention. Previous guidelines have supported light-based approaches for preventing mouth sores in certain cancer treatments, which fits with the strongest finding here. Evidence for broader benefits, such as improving daily function or shortening hospital stays, remains weaker and less consistent.

The most important limitation is the small sample of 30 patients, which makes the results fragile. The review also depends heavily on one main trial for its strongest conclusions. Some supporting sources were only available as short conference abstracts, and children’s studies may not apply directly to adults. In addition, the way light doses are measured and delivered is not yet fully standardized, which makes it harder to repeat results across different hospitals. Finally, the review cannot prove cause and effect for links between mouth sores and infections, pain medicine use, or nutrition.

The Bottom Line

Research suggests that light therapy may be a reasonable preventive option for severe mouth sores in defined stem cell transplant settings, with moderate confidence in that narrow use. Confidence is low for broader claims, such as improving hospital stays, physical strength, or quality of life. Patients should treat light therapy as a promising preventive tool rather than a complete supportive treatment, and decisions should be made with a transplant team.

This research is most relevant to people scheduled for stem cell transplants, their caregivers, and the clinicians who manage their care. It is less directly relevant to people with mouth sores from other causes, such as minor canker sores, and it does not apply in the same way to children without specialist guidance. Anyone without a transplant or related cancer treatment should not change their care based on these findings.

If light therapy is used, its preventive effect would be expected during the period when mouth sores are most likely to develop after high-dose treatment, which is usually within the first couple of weeks following transplant. Broader benefits, if they exist, have not been clearly demonstrated and would likely take longer to appear or require larger studies to confirm.

Frequently Asked Questions

Can light therapy prevent mouth sores from stem cell transplants?

Light therapy, called photobiomodulation, may reduce severe mouth sores in certain stem cell transplant settings. In the 30-patient POMFITT trial, 0 of 15 treated patients developed severe sores versus 4 of 15 controls. The evidence is limited, and larger studies are still needed.

What is oral mucositis?

Oral mucositis is painful inflammation and ulcers inside the mouth, a common side effect of the high-dose chemotherapy and radiation given before a stem cell transplant. It can make eating, drinking, and swallowing difficult. Researchers are studying ways, including light therapy, to lower its severity.

Does light therapy improve hospital stays or quality of life after a transplant?

Current evidence does not show clear benefits for hospital stays, physical function, or quality of life at discharge in the POMFITT trial. Findings from children’s studies and conference abstracts are preliminary. Light therapy should not yet be considered a full supportive-care treatment for transplant patients.

Want to Apply This Research?

  • Track the presence and severity of mouth sores each day on a simple 0 to 4 scale, noting pain level, whether you can eat normally, and whether you need prescribed mouth rinses or pain medicine. Also log the dates and times of any light therapy sessions so you can compare symptoms with treatment timing.
  • Use the app to set daily reminders for mouth care steps your care team recommends, such as gentle brushing, approved rinses, and staying hydrated. Log each completed reminder so you and your team can see patterns and discuss any changes in mouth comfort or eating.
  • Continue daily tracking through the transplant recovery period and into the following weeks, then review trends with your transplant team at each follow-up visit. Share summary reports of mouth pain, eating ability, and energy levels so your care team can judge whether preventive measures are working and adjust care as needed.

This article summarizes a research review for general education and is not medical advice. Anyone undergoing a stem cell transplant or considering light therapy for mouth sores should talk with their transplant team or oncologist before making any changes to their care.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Photobiomodulation for Oral Mucositis Prevention in Hematopoietic Stem Cell Transplantation: Evidence and Unresolved Supportive-Care Outcomes. , Photodiagnosis and photodynamic therapy (2026). PubMed 43057549 | DOI
Topics
photobiomodulation oral mucositis stem cell transplant mouth sores low-level light therapy supportive care POMFITT trial transplant recovery